Wireless Assessment of Respiratory and Circulatory Distress - Europe
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorEske Kvanner Aasvang
About this trial
Hospital patient monitoring in Europe is often intermittent, which can delay detection of clinical deterioration during hospitalization and after discharge. The WARD-EU study aims to describe current monitoring practices and to evaluate the feasibility, acceptability, and usability of the WARD-CSS (Wireless Assessment of Respiratory and Circulatory Distress - Clinical Support System), an algorithm-based continuous monitoring system. The study seeks to assess whether WARD-CSS can be integrated into routine hospital and post-discharge care to support earlier detection of patient deterioration and improved patient monitoring.
Eligibility criteria
Qualifiers
Adults (≥18 years) admitted to hospitals due to medical or surgical conditions with an expected hospital stay of at least two days.
Adults discharged from the hospital who are receiving home-based monitoring using WARD-CSS (Phase 2 only).
Willingness to participate and provide informed consent.
Disqualifiers
Patients with severe comorbidities (e.g., severe dementia) that preclude continuous monitoring.
Patients unwilling or unable to provide informed consent.
Patients unable to wear the monitoring equipment.
Trial design
Treatments tested in this trial
- WARD-CSS (Wireless Assessment of Respiratory and Circulatory Distress - Clinical Support System)
Treatment groups
1,240 Participants
are divided into 1 treatment groupSponsors and collaborators
Eske Kvanner Aasvang
Lead sponsor
Rigshospitalet, Denmark
Sponsor institution
Rigshospitalet, Denmark
Collaborator
University Medical Center Groningen, Netherland
Collaborator
NOVA Medical School
Collaborator
Jagiellonian University
Collaborator
Bispebjerg Hospital
Collaborator
Source ClinicalTrials.gov